KSH Holdings Limited (SGX:ER0)

Verve Therapeutics Ratios and Metrics

Market cap in millions SGD. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	149	116	148	192	197	197
Market Cap Growth	-21.27%	-21.27%	-22.84%	-2.86%	-	16.36%
Enterprise Value	163	162	233	284	266	274
Last Close Price	0.28	0.21	0.25	0.31	0.30	0.28
PE Ratio	-	-	-	8.66	8.16	-
Forward PE	-	8.65	8.65	8.65	8.65	8.65
PS Ratio	0.78	0.61	0.66	0.62	0.79	1.20
PB Ratio	0.50	0.39	0.47	0.53	0.55	0.57
P/TBV Ratio	0.53	0.42	0.50	0.57	0.59	0.62
P/FCF Ratio	5.33	4.17	-	-	4.34	10.60
P/OCF Ratio	5.12	4.01	-	-	4.30	9.83
EV/Sales Ratio	0.85	0.85	1.04	0.92	1.07	1.67
EV/EBITDA Ratio	59.34	10.52	-	20.45	105.53	-
EV/EBIT Ratio	137.51	11.44	-	22.77	259.80	-
EV/FCF Ratio	5.84	5.80	-	-	5.85	14.70
Debt / Equity Ratio	0.28	0.28	0.48	0.58	0.35	0.43
Debt / EBITDA Ratio	5.41	5.41	-	14.44	38.37	253.42
Debt / FCF Ratio	3.04	3.04	-	-	2.74	7.98
Asset Turnover	0.35	0.35	0.35	0.46	0.41	0.27
Quick Ratio	1.29	1.29	0.96	1.03	1.23	0.81
Current Ratio	1.59	1.59	1.23	1.27	1.57	1.17
Return on Equity (ROE)	-3.08%	-3.08%	-9.46%	6.16%	6.81%	-1.21%
Return on Assets (ROA)	1.62%	1.62%	-1.97%	1.17%	0.10%	-0.16%
Return on Capital (ROIC)	2.08%	2.08%	-2.44%	1.47%	0.13%	-0.20%
Return on Capital Employed (ROCE)	3.70%	3.70%	-	2.50%	0.20%	-
Earnings Yield	-3.99%	-5.10%	-21.00%	11.54%	12.25%	-1.92%
FCF Yield	18.77%	23.99%	-9.76%	-20.25%	23.07%	9.44%
Dividend Yield	5.36%	5.81%	3.97%	6.49%	6.68%	3.53%
Payout Ratio	-	-	-	50.96%	46.64%	-
Buyback Yield / Dilution	2.96%	2.96%	1.01%	-	0.09%	0.79%
Total Shareholder Return	8.31%	8.77%	4.98%	6.49%	6.77%	4.32%

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.